Novartis says has no intention of buying Actavis
ZURICH (Reuters) - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday.
"We have no intention to pursue them," spokesman Eric Althoff said in response to inquiries.
The Wall Street Journal earlier reported that Novartis - which operates a large generics business called Sandoz - was considering whether to enter the fray, after Actavis rebuffed separate takeover offers from Valeant Pharmaceuticals International Inc and Mylan Inc.
PORCIA, Italy - The boxy white and grey factory of this rainy northern town makes fewer than half the washing machines it did when Italy joined the euro. It is one of the many symbols of Southern Europe's industrial decline.
- U.S. small businesses borrowed more money in January than they did a year earlier, signaling continued growth in the economy despite a spate of cold weather that has been blamed for weakness in many other indicators of activity.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.